Brian H. Barber
Corporate Officer/Principal chez University of Toronto
Profil
Dr. Brian H.
Barber is an Advisor at VenGrowth Capital Partners, Inc. He is Vice President of Global Ventures for University Health Network Development Corp.
Prior to joining University Health Network Development, he was Chief Scientific Officer and Senior Vice President of Mojave Therapeutics, Inc. Before Mojave Therapeutics, he was an Assistant Vice President of Immunology for Aventis Pasteur.
Previously, he was a Professor of the Department of Immunology at the University of Toronto.
He is a Director of Inimex Pharmaceuticals, Inc. and Trillium Therapeutics, Inc. He is currently on the board of VenGrowth.
Dr. Barber received his undergraduate degree from McMaster University and a doctorate degree from the University of Toronto.
Postes actifs de Brian H. Barber
| Sociétés | Poste | Début |
|---|---|---|
| University of Toronto | Corporate Officer/Principal | 25/04/2011 |
Anciens postes connus de Brian H. Barber
| Sociétés | Poste | Fin |
|---|---|---|
VenGrowth Capital Partners, Inc.
 VenGrowth Capital Partners, Inc. Investment ManagersFinance Founded in 1982, VenGrowth Capital Partners, Inc. is a private equity and venture capital firm located in Toronto, Ontario. The firm is a subsidiary of Covington Capital Corp. They manage retail and institutional assets. | Corporate Officer/Principal | - |
Trillium Therapeutics, Inc. /Old/
 Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Directeur/Membre du Conseil | - |
Sanofi Pasteur, Inc.
 Sanofi Pasteur, Inc. Pharmaceuticals: MajorHealth Technology Sanofi Pasteur, Inc. provides vaccines for the prevention and treatment of diseases. It develops and manufactures influenza vaccine against the pandemic influenza virus. The company was founded in 1897 and is headquartered in Swiftwater, PA. | Corporate Officer/Principal | - |
Inimex Pharmaceuticals, Inc.
 Inimex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Inimex Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of Innate Defense Regulators (IDRs). IDRs are novel drugs that selectively trigger the body's innate defenses, protecting against antibiotic-resistant infections and controlling inflammation. The company was founded in 2001 and is headquartered in Vancouver, Canada. | Directeur/Membre du Conseil | - |
Formation de Brian H. Barber
| University of Toronto | Doctorate Degree |
| McMaster University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Inimex Pharmaceuticals, Inc.
Inimex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Inimex Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of Innate Defense Regulators (IDRs). IDRs are novel drugs that selectively trigger the body's innate defenses, protecting against antibiotic-resistant infections and controlling inflammation. The company was founded in 2001 and is headquartered in Vancouver, Canada. | Health Technology |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Commercial Services |
Sanofi Pasteur, Inc.
Sanofi Pasteur, Inc. Pharmaceuticals: MajorHealth Technology Sanofi Pasteur, Inc. provides vaccines for the prevention and treatment of diseases. It develops and manufactures influenza vaccine against the pandemic influenza virus. The company was founded in 1897 and is headquartered in Swiftwater, PA. | Health Technology |
VenGrowth Capital Partners, Inc.
VenGrowth Capital Partners, Inc. Investment ManagersFinance Founded in 1982, VenGrowth Capital Partners, Inc. is a private equity and venture capital firm located in Toronto, Ontario. The firm is a subsidiary of Covington Capital Corp. They manage retail and institutional assets. | Finance |
